2. Search Result
Search Result
Results for "

LDL-cholesterol

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

6

Peptides

4

Inhibitory Antibodies

1

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17504
    Rosuvastatin Calcium
    20+ Cited Publications

    Rosuvastatin hemicalcium; ZD 4522 Calcium

    		 HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium
  • HY-P99187
    Bococizumab

    PF-04950615; RN316

    		 PCSK9 Cardiovascular Disease Metabolic Disease
    Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
    Bococizumab
  • HY-112490
    Atorvastatin calcium hydrate
    Maximum Cited Publications
    65 Publications Verification

    		 HMG-CoA Reductase (HMGCR) Cardiovascular Disease Others
    Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
    Atorvastatin calcium hydrate
  • HY-17504A
    Rosuvastatin
    20+ Cited Publications

    ZD 4522

    		 HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin
  • HY-134124
    Glutathione ethyl ester

    		Reactive Oxygen Species (ROS) Metabolic Disease
    Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .
    Glutathione ethyl ester
  • HY-P9928
    Alirocumab
    1 Publications Verification

    REGN 727; SAR 236553

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
    Alirocumab
  • HY-17504B
    Rosuvastatin Sodium
    20+ Cited Publications

    ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium

    		 HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Sodium
  • HY-15790
    Elobixibat
    1 Publications Verification

    A 3309; AZD 7806

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat (A 3309; AZD 7806) is an orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to study metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat
  • HY-P9928A
    Alirocumab (anti-PCSK9)
    1 Publications Verification

    REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)

    		 PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1 Cardiovascular Disease Cancer
    Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
    Alirocumab (anti-PCSK9)
  • HY-10473
    Eprotirome

    KB2115

    		 Thyroid Hormone Receptor Metabolic Disease Endocrinology
    Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .
    Eprotirome
  • HY-15790A
    Elobixibat hydrate
    1 Publications Verification

    A 3309 hydrate; AZD 7806 hydrate

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Cancer
    Elobixibat (A 3309; AZD 7806) hydrate is an orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat hydrate can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to study metabolic syndrome. Elobixibat hydrate can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat hydrate
  • HY-145001
    20-HC-Me-Pyrrolidine

    		LDLR CETP Metabolic Disease
    20-HC-Me-Pyrrolidine (compound AI-3d) is a potent Aster protein inhibitor with IC50s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER) .
    20-HC-Me-Pyrrolidine
  • HY-N0857
    Deoxyandrographolide
    1 Publications Verification

    		 GLUT HDAC Virus Protease PI3K AMPK Akt Histone Demethylase MDM-2/p53 IFNAR Reactive Oxygen Species (ROS) Infection Metabolic Disease Inflammation/Immunology
    Deoxyandrographolide is an orally active lactone found in the Andrographis paniculata Nees. Deoxyandrographolide shows a KD of 38.4 μM of HDAC1. Deoxyandrographolide enhances GLUT4 plasma membrane translocation, activates PI3K and AMPK-dependent signaling pathways, suppresses fasting blood glucose, serum insulin, triglycerides, and LDL-cholesterol levels. Deoxyandrographolide enhances HDAC1 expression via inhibited ubiquitination degradation, represses H3K4me3, improves chromosome stability, and restrains aging biomarkers p16, p21, γH2A.X, p53 and ROS production. Deoxyandrographolide interacts with Foot-and-Mouth Disease Virus 3Cpro active site, inhibits protease and IFN-antagonist activity, derepresses ISG expression, and inhibits viral replication. Deoxyandrographolide can be used for the researches of type 2 diabetes mellitus, vascular senescence and virus infection .
    Deoxyandrographolide
  • HY-17504R
    Rosuvastatin Calcium (Standard)
    10+ Cited Publications

    Rosuvastatin hemicalcium (Standard); ZD 4522 Calcium (Standard)

    		 Reference Standards HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Calcium (Standard)
  • HY-17504AS1
    Rosuvastatin-d6

    ZD 4522-d6

    		 Isotope-Labeled Compounds Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin-d6 (ZD 4522-d6) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin-d6
  • HY-178015
    THR-β agonist 11

    		Thyroid Hormone Receptor Metabolic Disease Inflammation/Immunology
    THR-β agonist 11 is an orally active and selective thyroid hormone receptor (THR-β) agonist. THR-β agonist 11 shows potent cholesterol-lowering activity in cholesterol-fed rats. THR-β agonist 11 significantly reduces serum total TG, LDL-cholesterol, liver total TC and TG levels, and alleviates hepatic steatosis, inflammation and fibrosis in HFD-CCl4-induced Metabolic dysfunction-associated steatohepatitis (MASH) model mice. THR-β agonist 11 can be used for the study of metabolic dysfunction-associated steatohepatitis (MASH) and other fibrotic diseases .
    THR-β agonist 11
  • HY-17504BS1
    Rosuvastatin-d6 sodium

    		HMG-CoA Reductase (HMGCR) Autophagy Cardiovascular Disease Metabolic Disease
    Rosuvastatin-d6 sodium is deuterium labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    Rosuvastatin-d6 sodium
  • HY-108922
    Probucol disuccinate

    		Drug Derivative Metabolic Disease
    Probucol Disuccinate is a derivative of Probucol (HY-B0388), a lipid-regulating agent and can reduce LDL-cholesterol levels .
    Probucol disuccinate
  • HY-19251
    CL-283796

    		Acyltransferase Cardiovascular Disease Metabolic Disease
    CL-283796 is a potent and orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. CL-283796 reduces low-density lipoprotein (LDL) cholesterol without affecting cholesterol absorption in African green monkeys. CL-283796 can be used for hypercholesterolemia research .
    CL-283796
  • HY-15790H
    (S)-Elobixibat

    (S)-A 3309; (S)-AZD 7806

    		 Apical Sodium-Dependent Bile Acid Transporter TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology
    (S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to study metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .
    (S)-Elobixibat
  • HY-17504BR
    Rosuvastatin Sodium (Standard)

    ZD 4522 Sodium (Standard); X-Plended Sodium (Standard); Crestor Sodium (Standard)

    		 HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial Reference Standards Cardiovascular Disease Metabolic Disease Cancer
    Rosuvastatin (Sodium) (Standard) is the analytical standard of Rosuvastatin (Sodium). This product is intended for research and analytical applications. Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin Sodium (Standard)
  • HY-17504BS2
    Rosuvastatin-13C,d3 sodium

    ZD 4522-13C,d3 sodium; X-Plended-13C,d3 sodium; Crestor-13C,d3 sodium

    		 Autophagy Bacterial HMG-CoA Reductase (HMGCR) Potassium Channel Isotope-Labeled Compounds Cardiovascular Disease Metabolic Disease
    Rosuvastatin- 13C,d3 sodium is 13C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC50 of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    Rosuvastatin-13C,d3 sodium
  • HY-17504C
    (3R,5R)-Rosuvastatin

    		HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Cardiovascular Disease Metabolic Disease
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    (3R,5R)-Rosuvastatin
  • HY-17504D
    (3S,5R)-Rosuvastatin

    		HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Cardiovascular Disease Metabolic Disease
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM . Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .
    (3S,5R)-Rosuvastatin
  • HY-P2424
    Cholecystokinin-J

    CCK-J

    		 Calcium Channel Others
    Cholecystokinin-J (CCK-J), a cholecystokinin, stimulates Ca 2+ release .
    Cholecystokinin-J
  • HY-155006
    PCSK9-IN-19

    		PCSK9 Metabolic Disease
    PCSK9-IN-19 (Compound 1) is a PCSK9 inhibitor. PCSK9-IN-19 can be used for research of high LDL-cholesterol levels and prevention of coronary artery disease .
    PCSK9-IN-19
  • HY-P10906
    Talovirtide

    		Biochemical Assay Reagents Others
    Talovirtide is a peptide containing L-valyl .
    Talovirtide
  • HY-P11455
    Lipopeptide CPE4

    		Liposome Others
    Lipopeptide CPE4 is a PEG-modified peptide E4 [(EIAALEK) 4]. Lipopeptide CPE4 is capable of coiled-coil formation when attached to liposomes. Lipopeptide CPE4 triggers membrane fusion between liposomes and living cells with concomitant efficient cytosolic delivery of a variety of compounds such as fluorescent dyes Propidium Iodide (PI) (HY-D0815) and TO-PRO-3 iodide (HY-117070), and Doxorubicin (DOX) (HY-15142A). Lipopeptide CPE4 can be used for drug delivery research .
    Lipopeptide CPE4
  • HY-P10872
    P315V3

    		SARS-CoV Infection
    P315V3 is an pan inhibitor for coronavirus, that inhibits SARS-CoV-2 prototypePT, Delta, BA.1 and BA.4 strain with IC50s of 10.9, 8.9, 8.6, and 2.7 nM. P315V3 exhibits cytotoxicity in Vero cell with CC50 of 4.3 μM. P315V3 exhibits anti-infectious efficacy in mouse models .
    P315V3
  • HY-115357
    BMS711939

    		PPAR Metabolic Disease
    BMS711939 is a selective agonist for peroxisome proliferator-activated receptor α (PPAR α), with EC50 of 4 nM and 4.5 μM, for human PPARα and human PPARγ. BMS711939 exhibits good pharmacokinetic characters in rats models. BMS711939 increases HDL cholesterol, reduces LDL cholesterol and triglycerides .
    BMS711939
  • HY-15790S
    Elobixibat-d5

    A 3309-d5; AZD 7806-d5

    		 Isotope-Labeled Compounds Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat-d5
  • HY-15790R
    Elobixibat (Standard)

    A 3309 (Standard); AZD 7806 (Standard)

    		 Apical Sodium-Dependent Bile Acid Transporter Reference Standards Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat (Standard) is the analytical standard of Elobixibat (HY-15790). This product is intended for research and analytical applications. Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat (Standard)
  • HY-P11766
    GALA-chol

    GALA-cholesterol

    		 Biochemical Assay Reagents Cancer
    GALA-chol is a cholesterol-conjugated pH-responsive fusion peptide that can serve as a delivery adjuvant. GALA-chol enhances the endocytosis of siRNA RET/PTC1-SQ nanoparticles, inhibits cell viability, and undergoes pH-responsive charge conversion in the acidic lysosomal environment, thereby promoting lysosomal escape of small extracellular vesicle (sEV) cargo. GALA-chol anchors to the sEV membrane and maintains the structural integrity and intrinsic homing activity of sEVs. GALA-chol can be used in studies related to adjuvant delivery .
    GALA-chol
  • HY-10473R
    Eprotirome (Standard)

    KB2115 (Standard)

    		 Reference Standards Thyroid Hormone Receptor Metabolic Disease Endocrinology
    Eprotirome (Standard) is the analytical standard of Eprotirome (HY-10473). This product is intended for research and analytical applications. Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .
    Eprotirome (Standard)
  • HY-P992407
    MEDI-4166

    		PCSK9 GLP Receptor Inflammation/Immunology
    MEDI-4166 is an antibody-peptide gene fusion molecule of a PCSK9 antibody and a GLP-1 analog. MEDI-4166 is applicable to research related to type 2 diabetes .
    MEDI-4166

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: